Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 FUTURE OUTLOOK
11 REGULATORY COMPLIANCE
11.1 REGULATORY AUTHORITIES
11.2 REGULATORY CLASSIFICATIONS
11.2.1 CLASS I
11.2.2 CLASS II
11.2.3 CLASS III
11.3 REGULATORY SUBMISSIONS
11.4 INTERNATIONAL HARMONIZATION
11.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
11.6 REGULATORY CHALLENGES AND STRATEGIES
12 REIMBURSEMENT FRAMEWORK
13 OPPUTUNITY MAP ANALYSIS
14 VALUE CHAIN ANALYSIS
15 HEALTHCARE ECONOMY
15.1 HEALTHCARE EXPENDITURE
15.2 CAPITAL EXPENDITURE
15.3 CAPEX TRENDS
15.4 CAPEX ALLOCATION
15.5 FUNDING SOURCES
15.6 INDUSTRY BENCHMARKS
15.7 GDP RATION IN OVERALL GDP
15.8 HEALTHCARE SYSTEM STRUCTURE
15.9 GOVERNMENT POLICIES
15.1 ECONOMIC DEVELOPMENT
16 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY PRODUCT TYPE
16.1 OVERVIEW
16.2 INSTRUMENTS
16.2.1 BY MODE
16.2.1.1. FULLY-AUTOMATED
16.2.1.2. SEMI-AUTOMATED
16.2.2 BY THROUGHPUT LEVEL
16.2.2.1. MEDIUM
16.2.2.2. HIGH
16.2.3 BY NUCLEIC ACID TYPE
16.2.3.1. RNA
16.2.3.2. DNA
16.2.3.3. HYBRID
16.2.4 BY MODALITY
16.2.4.1. BENCHTOP
16.2.4.2. STANDALONE
16.2.4.3. PORTABLE
16.2.5 BY SAMPLE VOLUME
16.2.5.1. 10~1000 µL
16.2.5.2. 1000~2000 µL
16.2.5.3. 0.2-1ML
16.2.5.4. OTHERS
16.3 KITS & CONSUMABLES
16.3.1 NUCLEIC ACID EXTRACTION KITS
16.3.1.1. BY TYPE
16.3.1.1.1. 48 T
16.3.1.1.2. 24 T
16.3.1.1.3. 96 T
16.3.1.1.4. OTHERS
16.3.1.2. BY CATEGORY
16.3.1.2.1. SINGLE TYPE EXTRACTION KIT
16.3.1.2.2. MULTI-TYPE EXTRACTION KIT
16.3.2 MAGNETIC BEADS
16.3.3 WELL PLATES
16.3.4 TIP COMBS SETS
16.3.5 BINDING COLUMNS
16.3.6 BUFFERS
16.3.7 SPIN COLUMNS
16.3.8 OTHERS
16.4 OTHERS
17 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY TECHNOLOGY
17.1 OVERVIEW
17.2 MAGNETIC BEADS TECHNOLOGY (MB)
17.3 ONE-TUBE FAST RELEASE TECHNOLOGY (OT)
17.4 PARTICLE MOVER TECHNOLOGY
17.5 OTHERS
18 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY SAMPLE TYPE
18.1 OVERVIEW
18.2 PLASMA
18.3 SERUM
18.4 WHOLE BLOOD
18.5 SALIVA
18.6 URINE
18.7 TISSUE
18.8 SECRETIONS
18.9 EXFOLIATED CELLS,
18.1 NASOPHARYNGEAL SWAB
18.11 OROPHARYNGEAL SWAB
18.12 FECES
18.13 OTHERS
19 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 CLINICAL
19.2.1 SEXUALLY TRANSMITTED DISEASES
19.2.1.1. CHLAMYDIA
19.2.1.2. HSV-2
19.2.1.3. HSV I/2
19.2.1.4. OTHERS
19.2.2 WOMEN’S HEALTH
19.2.3 RESPIRATORY TRACT DISEASE
19.2.3.1. RESPIRATORY SYNCYTIAL VIRUS
19.2.3.2. TUBERCULOSIS
19.2.3.3. MYCOPLASMA PNEUMONIAE INFECTION
19.2.3.4. OTHERS
19.2.4 GASTROINTESTINAL DISEASES
19.2.5 PRENATAL AND POSTNATAL CARE
19.2.6 INFECTIOUS DISEASES
19.2.6.1. SARS-COV-2
19.2.6.2. INFLUENZA A/B
19.2.6.3. HINI
19.2.6.4. H7N9
19.2.6.5. OTHERS
19.3 RESEARCH
20 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITALS
20.2.1 BY TYPE
20.2.1.1. PRIVATE
20.2.1.1.1. TIER 1
20.2.1.1.2. TIER 2
20.2.1.1.3. TIER 3
20.2.1.2. PUBLIC
20.2.1.2.1. TIER 1
20.2.1.2.2. TIER 2
20.2.1.2.3. TIER 3
20.3 DIAGNOSTIC CENTERS
20.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
20.5 ACADEMIC AND RESEARCH ORGANIZATIONS
20.6 OTHERS
21 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL SALES
21.4 OTHERS
22 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, SWOT AND DBMR ANALYSIS
23 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT & APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, BY REGION
GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
24.1 NORTH AMERICA
24.1.1 U.S.
24.1.2 CANADA
24.1.3 MEXICO
24.2 EUROPE
24.2.1 GERMANY
24.2.2 U.K.
24.2.3 ITALY
24.2.4 FRANCE
24.2.5 SPAIN
24.2.6 RUSSIA
24.2.7 SWITZERLAND
24.2.8 TURKEY
24.2.9 BELGIUM
24.2.10 NETHERLANDS
24.2.11 DENMARK
24.2.12 SWEDEN
24.2.13 POLAND
24.2.14 NORWAY
24.2.15 FINLAND
24.2.16 REST OF EUROPE
24.3 ASIA-PACIFIC
24.3.1 JAPAN
24.3.2 CHINA
24.3.3 SOUTH KOREA
24.3.4 INDIA
24.3.5 SINGAPORE
24.3.6 THAILAND
24.3.7 INDONESIA
24.3.8 MALAYSIA
24.3.9 PHILIPPINES
24.3.10 AUSTRALIA
24.3.11 NEW ZEALAND
24.3.12 VIETNAM
24.3.13 TAIWAN
24.3.14 REST OF ASIA-PACIFIC
24.4 SOUTH AMERICA
24.4.1 BRAZIL
24.4.2 ARGENTINA
24.4.3 REST OF SOUTH AMERICA
24.5 MIDDLE EAST AND AFRICA
24.5.1 SOUTH AFRICA
24.5.2 EGYPT
24.5.3 BAHRAIN
24.5.4 UNITED ARAB EMIRATES
24.5.5 KUWAIT
24.5.6 OMAN
24.5.7 QATAR
24.5.8 SAUDI ARABIA
24.5.9 REST OF MEA
24.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
25 GLOBAL AUTOMATED NUCLEIC ACID EXTRACTION DEVICES MARKET, COMPANY PROFILE
25.1 BIO-RAD LABORATORIES, INC.
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPMENTS
25.2 ESCO MICRO PTE. LTD.
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPMENTS
25.3 QIAGEN
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPMENTS
25.4 AUTOGEN INC.
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPMENTS
25.5 THERMO FISHER SCIENTIFIC INC.
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPMENTS
25.6 PERKINELMER INC.
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPMENTS
25.7 MP BIOMEDICALS
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPMENTS
25.8 GENEREACH BIOTECHNOLOGY CORP.
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPMENTS
25.9 PROMEGA CORPORATION
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPMENTS
25.1 HOFFMANN-LA ROCHE LTD
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPMENTS
25.11 ANALYTIK JENA GMBH+CO. KG
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPMENTS
25.12 ACCUBIOMED CO., LTD.
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPMENTS
25.13 BIONEER CORPORATION
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPMENTS
25.14 TECAN TRADING AG
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPMENTS
25.15 BD
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPMENTS
25.16 HAMILTON COMPANY
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPMENTS
25.17 AURORA BIOMED INC.
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPMENTS
25.18 JIANGSU BIOPERFECTUS TECHNOLOGIES CO., LTD
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPMENTS
25.19 ADS BIOTEC INC.
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPMENTS
25.2 SEEGENE INC.
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPMENTS
26 RELATED REPORTS
27 CONCLUSION
28 QUESTIONNAIRE
29 ABOUT DATA BRIDGE MARKET RESEARCH
